Bayer Yakuhin To Sell Kobe Research Lab (Japan)
This article was originally published in PharmAsia News
Bayer Yakuhin Ltd., a Japanese subsidiary of German pharmaceutical firm Bayer Schering Pharma AG, plans to close a Kobe research laboratory before the end of the year and sell it. The move is part of Bayer's effort to streamline operations after it acquired last year German drugmaker Schering AG and in July consolidated the two firms' Japanese units. The lab has been involved in basic research, including stem cell cultivation, achieving some breakthroughs. Following the merger, however, Bayer Schering decided to concentrate research on cancer, heart disease, gynecological disorders and diagnostic imaging drugs. (Click here for more - May Require Paid Subscription
You may also be interested in...
TOKYO - Bayer Shering Pharma AG has submitted patent applications for its induced pluripotent stem cell manufacturing method with the Japan Patent Office, the first foreign entity to seek intellectual property rights protection for an iPS method after one filed by Kyoto University Professor Shinya Yamanaka, according to Bayer's patent filing released by JPO Dec. 25, 2008
The German pricing and reimbursement system has been successful in recognizing the value and uniqueness of orphan drugs.
Erectile problems prevent a quarter of Brits from being intimate with a partner. Viatris' Upjohn - which markets Viagra Connect in the UK - is working with the Men’s Health Forum, sexual health charity Brook and dating expert Sarah Louise Ryan raise awareness of the problem and get men talking about the issue with their partners and with healthcare professionals.